STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug

▤ Summary

Lilly released new safety and tolerability data for retatrutide, its next-generation obesity drug. The update adds detail to a late-stage diabetes study that already showed strong blood sugar reduction and significant weight loss. Researchers reported arrhythmias in seven of 403 treated participants and major cardiovascular complications in three treated participants, with none in the placebo group. Experts said the event counts were too small to support meaningful conclusions. The findings were presented at the American Diabetes Association meeting and published in The Lancet.

▦ Linked Companies